Anti-obesity therapy: from rainbow pills to polyagonists

TD Müller, C Clemmensen, B Finan, RD DiMarchi… - Pharmacological …, 2018 - ASPET
With their ever-growing prevalence, obesity and diabetes represent major health threats of
our society. Based on estimations by the World Health Organization, approximately 300 …

An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action

RP Shank, JF Gardocki, AJ Streeter, BE Maryanoff - Epilepsia, 2000 - Wiley Online Library
In this overview, we discuss the discovery and development of topiramate (TPM) as an
anticonvulsant, including notable aspects of its chemical, biologic, and pharmacokinetic …

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

BA Johnson, N Ait-Daoud, CL Bowden… - The Lancet, 2003 - thelancet.com
Background Topiramate, a sulphamate fructopyranose derivative, might antagonise
alcohol's rewarding effects associated with abuse liability by inhibiting mesocorticolimbic …

Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity

KY Chen, RJ Brychta, ZA Sater, TM Cassimatis… - Journal of biological …, 2020 - ASBMB
The current obesity pandemic results from a physiological imbalance in which energy intake
chronically exceeds energy expenditure (EE), and prevention and treatment strategies …

Topiramate for treating alcohol dependence: a randomized controlled trial

BA Johnson, N Rosenthal, JA Capece, F Wiegand… - Jama, 2007 - jamanetwork.com
ContextHypothetically, topiramate can improve drinking outcomes among alcohol-
dependent individuals by reducing alcohol's reinforcing effects through facilitation of γ …

Narrative review of topiramate: clinical uses and pharmacological considerations

NZ Pearl, CP Babin, NT Catalano, JC Blake… - Advances in …, 2023 - Springer
Due to the diverse mechanisms of action of antiseizure drugs, there has been a rise in
prescriptions of these drugs for non-epileptic pathologies. One drug that is now being used …

Centrally acting agents for obesity: past, present, and future

AA Coulter, CJ Rebello, FL Greenway - Drugs, 2018 - Springer
For many years, obesity was believed to be a condition of overeating that could be resolved
through counseling and short-term drug treatment. Obesity was not recognized as a chronic …

Drug interactions at GABAA receptors

ER Korpi, G Gründer, H Lüddens - Progress in neurobiology, 2002 - Elsevier
Neurotransmitter receptor systems have been the focus of intensive pharmacological
research for more than 20 years for basic and applied scientific reasons, but only recently …

[HTML][HTML] Molecular mechanisms of antiseizure drug activity at GABAA receptors

LJ Greenfield Jr - Seizure, 2013 - Elsevier
Abstract The GABA A receptor (GABA AR) is a major target of antiseizure drugs (ASDs). A
variety of agents that act at GABA A Rs s are used to terminate or prevent seizures. Many act …

Carbonic anhydrase inhibitors and epilepsy: State of the art and future perspectives

L Ciccone, C Cerri, S Nencetti, E Orlandini - Molecules, 2021 - mdpi.com
Carbonic anhydrases (CAs) are a group of ubiquitously expressed metalloenzymes that
catalyze the reversible hydration/dehydration of CO2/HCO3. Thus, they are involved in those …